89947-79-5 Usage
Description
1-Palmitoyl-2-(4-carboxybutanoyl)-sn-glycero-3-phosphatidylcholine, also known as POV-PC, is a phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. It is one of the low molecular weight species found in oxidized low-density lipoprotein (oxLDL) particles and has been identified as a potent PPARγ agonist.
Uses
Used in Pharmaceutical Industry:
1-Palmitoyl-2-(4-carboxybutanoyl)-sn-glycero-3-phosphatidylcholine is used as a pharmaceutical agent for its potential role in modulating inflammatory responses. It has been shown to stimulate monocyte binding and strongly inhibit the LPS-induced binding of neutrophils, making it a promising candidate for the treatment of inflammatory conditions.
Used in Research Applications:
POV-PC is used as a research tool to study the effects of oxidized lipids on cellular processes and their role in various diseases. It helps researchers understand the mechanisms by which oxLDL particles contribute to the development of atherosclerosis and other inflammatory disorders.
Used in Drug Development:
1-Palmitoyl-2-(4-carboxybutanoyl)-sn-glycero-3-phosphatidylcholine is used in drug development as a potential therapeutic target for the treatment of atherosclerosis and other related conditions. Its agonistic activity towards PPARγ suggests that it may have beneficial effects on lipid metabolism and inflammation, making it a valuable compound for the development of new drugs targeting these pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 89947-79-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,9,4 and 7 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 89947-79:
(7*8)+(6*9)+(5*9)+(4*4)+(3*7)+(2*7)+(1*9)=215
215 % 10 = 5
So 89947-79-5 is a valid CAS Registry Number.
89947-79-5Relevant articles and documents
Lecithinization of IL-6 enhances its thrombopoietic activity in mice
Igarashi,Tsutsumi,Fujii,Tsunoda,Ochiai,Takenaga,Morizawa,Mayumi,Mizushima
, p. 113 - 118 (1997)
This study was conducted to assess the merit of lecithinization of recombinant human interleukin-6 (IL-6) as a drug delivery system. IL-6 was lecithinized by covalently binding it with a phosphatidylcholine (lecithin, PC) derivative. The in-vivo thrombopoietic potency of lecithinized IL-6 (PC-IL-6) was greater than that of native IL-6 when administered subcutaneously, although the in-vitro bioactivity of PC-IL-6 was markedly reduced by lecithinization. When PC-IL-6 and native IL-6 were given in doses that produced the same level of thrombopoietic activity, the former stimulated less production of IgG1, a marker of the adverse effects of IL-6, than did the latter. Furthermore, PC-IL-6 persisted in the blood longer than native IL-6. Based on the above, PC-IL-6 appears to be useful as a drug delivery system and may also be useful in the treatment of drug-induced thrombocytopenia.
